- Nxera Pharma Japan has received approval to establish a **second API manufacturing facility in Asia** for its insomnia treatment, QUVIVIQ® (daridorexant) 25 and 50 mg, in addition to its primary European site.  **[1625288_f83da8e2c7914d8bb373ae9ae0ba14d7_1]** **[1625288_f83da8e2c7914d8bb373ae9ae0ba14d7_2]** 
- This expansion aims to address **expected demand growth** for QUVIVIQ® in Japan and the broader Asia-Pacific region, where the product was launched in Japan in **December 2024**.  **[1625288_f83da8e2c7914d8bb373ae9ae0ba14d7_1]** **[1625288_f83da8e2c7914d8bb373ae9ae0ba14d7_2]** 
- The new facility is projected to **reduce manufacturing costs** and enhance profitability, with cost reduction benefits expected to begin in **2027** and contribute to the company's **2030 Vision** of sales exceeding **JPY 50 billion** and a profit margin over **30%**.  **[1625288_f83da8e2c7914d8bb373ae9ae0ba14d7_1]** **[1625288_f83da8e2c7914d8bb373ae9ae0ba14d7_0]** 
- Nxera's full-year sales forecast for QUVIVIQ® for the fiscal year ending December 2025 is **JPY 4.0 to JPY 5.0 billion**.  **[1625288_f83da8e2c7914d8bb373ae9ae0ba14d7_1]**

NEXIEN BIOPHARMA (NXEN)